home / stock / pmn:cc / pmn:cc news

PMN:CC News and Press, Promis Neurosciences Inc. From 07/17/23

Stock Information
Company Name: Promis Neurosciences Inc.
Stock Symbol: PMN:CC
Market: TSXC
Website: promisneurosciences.com
Menu
PMN:CC PMN:CC Quote PMN:CC Short PMN:CC News PMN:CC Articles PMN:CC Message Board
Get PMN:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
PMN:CC - ProMIS Showcases Preclinical Data at the Alzheimer's Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer's Pipeline

New findings highlight that PMN310 was able to target toxic amyloid-beta oligomers more selectively than other amyloid-beta-directed antibodies which were generated using synthetic oligomers Rationally designed vaccine candidate for prevention of Alzheimer’s disease showed robust and...
PMN:CC - ProMIS Announces Completion of Continuance

TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 14, 2023 (GLOBE NEWSWIRE) -- ProMIS Neur osciences Inc. (TSX: PMN) (NASDAQ: PMN ) (“ProMIS” or the “Corporation”) is pleased to announce that it has completed its continuance (the “ Continuanc...

PMN:CC - ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

Company to voluntarily delist from the Toronto Stock Exchange (TSX) Last trading day on TSX will be July 21, 2023 TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 10, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company fo...

PMN:CC - ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved

TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 30, 2023 (GLOBE NEWSWIRE) -- ProMIS Neur osciences Inc. (TSX: PMN) (NASDAQ: PMN ) , a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerativ...
PMN:CC - CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time

TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 29, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (NASDAQ: PMNRFXF) (“ ProMIS ” or the “Corporation”) is issuing this release to correct the URL required to virtually access the Cor...

PMN:CC - ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

Received FDA clearance for investigational new drug (IND) application for lead therapeutic candidate, PMN310, in Alzheimer’s disease Presented preclinical data supporting target identification and candidate differentiation across pipeline of antibody therapeutics at international neuro...

PMN:CC - ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer's Disease

TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 08, 2023 (GLOBE NEWSWIRE) -- In pre clinical studies, PMN310 demonstrated the abilit y to selectively target and protect against pathogenic Aβ oligomers The IND clearance of PMN310 in the...
PMN:CC - Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer's Disease

Findings support Aβ vaccine candidate consisting of conformational B cell epitope of Aβ oligomers conjugated to a carrier protein as a potential strategy for preventing Alzheimer’s disease progression TORONTO, Ontario and CA...

PMN:CC - ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer's Disease and ALS at American Academy of Neurology Annual Meeting

Lead therapeutic candidate for Alzheimer’s disease, PMN310, demonstrate d selective binding and protection against toxic amyloid-beta oligomers Preclinical data support misfolded RACK1 as a potential target for ALS and FTLD-TDP TORONTO, Ontario and CAMBRIDGE, Ma...

PMN:CC - ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310

TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 10, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as...
Previous 10 Next 10